Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.95 EUR | +0.63% | +3.36% | -29.17% |
25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Sales 2024 * | 60.73M 64.94M 5.42B | Sales 2025 * | 70.75M 75.65M 6.31B | Capitalization | 706M 754M 62.92B |
---|---|---|---|---|---|
Net income 2024 * | -12M -12.83M -1.07B | Net income 2025 * | 11M 11.76M 981M | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | 70.67M 75.56M 6.3B | Net cash position 2025 * | 74.87M 80.05M 6.68B | EV / Sales 2025 * | 8.91 x |
P/E ratio 2024 * |
-74
x | P/E ratio 2025 * |
521
x | Employees | 224 |
Yield 2024 * |
-
| Yield 2025 * |
0.61% | Free-Float | 42.17% |
1 day | +0.63% | ||
1 week | +3.36% | ||
Current month | -13.81% | ||
1 month | -12.20% | ||
3 months | -19.13% | ||
6 months | -25.05% | ||
Current year | -29.17% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Glombitza
CEO | Chief Executive Officer | - | 01/16/01 |
Enno Spillner
DFI | Director of Finance/CFO | 55 | 01/23/01 |
Andreas Seidl
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olaf Stiller
FOU | Founder | 47 | 01/07/01 |
Peter Wendeln
BRD | Director/Board Member | 59 | - |
Klaus Röhrig
BRD | Director/Board Member | 47 | 10/20/10 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.47% | 17 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 39.95 | +0.63% | 4,802 |
25/24/25 | 39.7 | +1.53% | 5,054 |
24/24/24 | 39.1 | 0.00% | 6,386 |
23/24/23 | 39.1 | +2.36% | 16,546 |
22/24/22 | 38.2 | -1.16% | 24,448 |
Delayed Quote Xetra, April 26, 2024 at 09:06 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.17% | 753M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FYB Stock